Key points are not available for this paper at this time.
Advanced cancer of the prostate is L relatively prevalent, and, in this country, it is now the third most common cause of death due to cancer in the male.5Endocrine treatment in this stage has resulted in a variable and unpredictable and, in most cases, an unsustained restraint of tumor growth; therapy with estrogens has been reported to increase the mortality from cardiovascular disease to about the same extent that it diminishes the death rate due to cancer.6As a result, interest has been focused on the earlier stages of prostatic cancer to learn how it develops, how rapidly it grows, whether endocrine treatment in an early stage is more beneficial than in an advanced stage, and whether radical excision in the early stage is superior to any other type of treatment in controlling or eradicating the disease. For years, pathologists have described the beginnings of prostatic cancer
Hugh J. Jewett (Mon,) studied this question.